Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
Clinical Trial Observations: Aethlon Medical reported preliminary findings from its oncology clinical trial in Australia, indicating encouraging changes in extracellular vesicles (EVs), microRNAs, and lymphocyte counts in three patients treated with the Hemopurifier, a device aimed at cancer patients unresponsive to anti-PD-1 therapy.
Caveats and Limitations: The results are based on a small cohort, with only directional statistics available, and cannot confirm clinical efficacy or safety. Further data from additional cohorts is needed to assess reproducibility and potential dose responses.
Get Free Real-Time Notifications for Any Stock
Analyst Views on AEMD
About AEMD
About the author
Aethlon Medical Secures $3.3 Million Financing to Accelerate Cancer Treatment
- Financing Agreement: Aethlon Medical has entered into a securities purchase agreement with a single institutional investor to sell 595,897 shares and warrants for 1,042,820 shares, raising approximately $3.3 million, expected to close on December 8, 2025, enhancing liquidity for R&D support.
- Warrant Inducement: The company has negotiated a warrant inducement agreement to lower the exercise price of March and September 2025 warrants to $4.03, which is expected to encourage the investor to exercise these warrants, providing additional funding for the company.
- Market Compliance: This financing adheres to Nasdaq rules under Section 4(a)(2) of the Securities Act, ensuring the company's compliance in capital markets, which enhances investor confidence and improves the company's reputation.
- Future Growth Potential: Aethlon is focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases, and this financing will accelerate clinical trial processes, boosting the company's competitiveness in the medical device sector.
American Eagle Shares Rise 15%; Check Out 20 Stocks Making Moves in Premarket Trading
American Eagle Outfitters Performance: American Eagle Outfitters Inc. reported third-quarter revenue of $1.36 billion and adjusted earnings of 53 cents per share, both exceeding analyst expectations, leading to a 14.8% increase in share price during pre-market trading.
Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including Powell Max Ltd (up 70%), Creative Media & Community Trust Corp (up 53.3%), and SMX (up 27.3%).
Significant Losers: Lulu’s Fashion Lounge Holdings Inc. experienced a dramatic drop of 58.3%, while ScanTech AI Systems Inc. fell 35.8% after receiving a delisting determination from Nasdaq.
Market Reactions: The overall market showed mixed reactions with various companies reporting earnings and guidance updates, impacting their stock prices significantly in pre-market trading.
